(Q46630506)

23 December 2017

title

Baseline characteristics of patients enrolled in EXCELS: a cohort study (English)

1 reference

23 December 2017

9

Stanley J Szefler

1 reference

23 December 2017

Aidan A Long

1

1 reference

23 December 2017

James E Fish

2

1 reference

23 December 2017

Abdelkader Rahmaoui

3

1 reference

23 December 2017

Mary K Miller

4

1 reference

23 December 2017

Mary S Bradley

5

1 reference

23 December 2017

Hassan N Taki

6

1 reference

23 December 2017

Anthony N Demeo

7

1 reference

23 December 2017

Stephen A Tilles

8

1 reference

23 December 2017

publication date

1 September 2009

1 reference

23 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

23 December 2017

volume

103

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

212-219

1 reference

23 December 2017

Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Trends in childhood asthma: prevalence, health care utilization, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Population disparities in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Inadequate use of asthma medication in the united states: Results of the asthma in america national population survey

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Omalizumab improves asthma-related quality of life in children with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Development of the asthma control test: a survey for assessing asthma control

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Predictors of asthma control in a random sample of asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

The validity and reproducibility of a work productivity and activity impairment instrument

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Race and sex differences in consistency of care with national asthma guidelines in managed care organizations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Differing reports of asthma symptoms in African Americans and Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

The associations between smoking, physical inactivity, obesity, and asthma severity in the general US population

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Improvement in quality of life with omalizumab in patients with severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960184-6

7 January 2021

10.1016/S1081-1206(10)60184-6

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017